Search Results - "Baim, Arielle"

A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia by Murthy, Guru Subramanian Guru, Saliba, Antoine N, Szabo, Aniko, Harrington, Alexandra, Abedin, Sameem, Carlson, Karen, Michaelis, Laura, Runaas, Lyndsey, Baim, Arielle, Hinman, Alex, Maldonado-Schmidt, Sonia, Venkatachalam, Annapoorna, Flatten, Karen S, Peterson, Kevin L, Schneider, Paula A, Litzow, Mark, Kaufmann, Scott H, Atallah, Ehab

“…Azacitidine/venetoclax is an active regimen in patients with newly diagnosed acute myeloid leukemia (AML). However, primary or secondary resistance to…”
Get full text

A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B‐cell non‐Hodgkin lymphoma: A Wisconsin Oncology Network study by Fenske, Timothy S., Shah, Namrata M., Kim, Kyung Mann, Saha, Sandeep, Zhang, Chong, Baim, Arielle E., Farnen, John P., Onitilo, Adedayo A., Blank, Jules H., Ahuja, Harish, Wassenaar, Tim, Qamar, Rubina, Mansky, Patrick, Traynor, Anne M., Mattison, Ryan J., Kahl, Brad S.

“…BACKGROUND Proteasome inhibitors and mammalian target of rapamycin inhibitors each have activity in various B‐cell malignancies and affect distinct cellular…”
Get full text

A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasm by Dong, Athena, Pan, Xiaoqing, Lin, Chien-Wei, Huang, Yi-Wen, Krause, Hayden, Pan, Pan, Baim, Arielle, Thomas, Michael J, Chen, Xiao, Yu, Jianhua, Michaelis, Laura, Liu, Pengyuan, Wang, Li-Shu, Atallah, Ehab

“…Myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are bone marrow disorders characterized by cytopenias and…”
Get full text

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia by Guru Murthy, Guru Subramanian, Shah, Bijal D., Duvall, Adam S, Leonard, Jessica T., Badar, Talha, Arana Yi, Cecilia Y., Kearl, Tyce, Baim, Arielle, Harrington, Alexandra M., Szabo, Aniko, Atallah, Ehab L.

“…Background: Outcomes of adults with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) has remained poor. CD38 is a transmembrane glycoprotein…”
Get full text

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with CD38 Expressing Relapsed/Refractory Acute Myeloid Leukemia by Guru Murthy, Guru Subramanian, Leonard, Jessica T., Badar, Talha, Arana Yi, Cecilia Y., Duvall, Adam S, Shah, Bijal D., Baim, Arielle, Kearl, Tyce, Harrington, Alexandra M., Szabo, Aniko, Atallah, Ehab L.

“…Background: Outcomes of adults with relapsed/refractory acute myeloid leukemia (RR-AML) have remained poor. CD38 is a transmembrane glycoprotein that is highly…”
Get full text

Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study by Mauro, Michael, Visotcky, Alexis, Flynn, Kathryn E, Radich, Jerald P., Yang, Jay, Oehler, Vivian G., Cortes, Jorge E., Kota, Vamsi K, Tantravahi, Srinivas K., Baim, Arielle, Zhang, Mei-Jie, Hinman, Alexander, Atallah, Ehab L., Sweet, Kendra

Get full text

A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with CD38 expressing relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia by Guru Murthy, Guru Subramanian, Kearl, Tyce, Cui, Weigo, Johnson, Bryon, Hoffmeister, Karin, Harrington, Alexandra, Szabo, Aniko, Badar, Talha, Duvall, Adam, Leonard, Jessica Taft, Arana Yi, Cecilia Ysabel, Baim, Arielle, Yaghoubi, Shahriar, Shah, Bijal D., Stock, Wendy, Atallah, Ehab L.

“…TPS7070 Background: Outcomes of adults with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML) have remained…”
Get full text

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice by Thompson, James E, Gao, Yan, Visotcky, Alexis, Flynn, Kathryn E, Mauro, Michael, Giever, Emily, Baim, Arielle, Akinola, Idayat, Larson, Richard, Jamy, Omer, Hunter, Anthony M., Kota, Vamsi K., Cortes, Jorge, Druker, Brian J., Shah, Neil P., Pinilla-Ibarz, Javier, Yang, Jay, Ritchie, Ellen K., Rein, Lindsay A.M, Smith, B. Douglas, Tantravahi, Srinivas K., Badar, Talha, Deininger, Michael W., Atallah, Ehab L.

“…Background: First-line therapies for chronic-phase (CP) CML include the tyrosine kinase inhibitors(TKIs) dasatinib, nilotinib, bosutinib or imatinib, while…”
Get full text

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice by Mauro, Michael, Atallah, Ehab L., Thompson, James E, Gao, Yan, Visotcky, Alexis, Giever, Emily, Baim, Arielle, Akinola, Idayat, Larson, Richard A., Jamy, Omer, Cortes, Jorge, Druker, Brian J., Shah, Neil P., Pinilla-Ibarz, Javier, Yang, Jay, Ritchie, Ellen K., Rein, Lindsay A.M, Tantravahi, Srinivas K., Badar, Talha, Smith, B. Douglas, Deininger, Michael W., Flynn, Kathryn E

“…Background and significance: There are typically high response rates to first line TKI therapies in chronic phase chronic myeloid leukemia (CP-CML). However,…”
Get full text

Second Treatment Free Remission after Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CML) by Sweet, Kendra, Atallah, Ehab L., Radich, Jerry P., Zhang, Mei-Jie, Sahakian, Eva, Mediavilla-Varela, Melanie, Vistocky, Alexis, Heinrich, Michael C., Thompson, James E., Mauro, Michael J., Flynn, Kathryn E, Baim, Arielle, Pinilla Ibarz, Javier

“…Background: Discontinuation of tyrosine kinase inhibitors (TKIs) is feasible in a subset of CML patients who have maintained a deep molecular response for at…”
Get full text

A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML) by Guru Murthy, Guru Subramanian, Kaufmann, Scott H., Szabo, Aniko, Harrington, Alexandra M., Michaelis, Laura C., Abedin, Sameem, Carlson, Karen, Runaas, Lyndsey, Longo, Walter L., Hinman, Alexander, Maldonado-Schmidt, Sonia, Thomas, Althea, Baim, Arielle, Litzow, Mark R., Atallah, Ehab L.

“…Background: Outcomes of patients with relapsed/refractory AML (RR-AML) have remained poor. Therapy with venetoclax based combinations in this setting leads to…”
Get full text

Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study by Atallah, Ehab L., Visotcky, Alexis, Flynn, Kathryn E, Zhang, Mei-Jie, Radich, Jerald P., Yang, Jay, Oehler, Vivian G., Tantravahi, Srinivas K., Smith, B. Douglas Douglas, Pinilla Ibarz, Javier, Sweet, Kendra, Mauro, Michael, Druker, Brian J., Thompson, James E., Maldonado-Schmidt, Sonia, Baim, Arielle, Schiffer, Charles A., Kota, Vamsi K., Cortes, Jorge E.

Get full text

Building a National CML Registry by Atallah, Ehab L., Singavi, Arun K, Taylor, Bradley, Baim, Arielle, Myers, Judith, Giever, Emily, Neuner, Joan, Shaw, Bronwen E., Flynn, Kathryn E

“…Background: Tyrosine kinase inhibitor (TKI) therapy has led to phenomenal improvement in overall survival for patients with CML. Since TKI therapies were…”
Get full text

Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial by Atallah, Ehab, Schiffer, Charles A, Radich, Jerald P, Weinfurt, Kevin P, Zhang, Mei-Jie, Pinilla-Ibarz, Javier, Kota, Vamsi, Larson, Richard A, Moore, Joseph O, Mauro, Michael J, Deininger, Michael W N, Thompson, James E, Oehler, Vivian G, Wadleigh, Martha, Shah, Neil P, Ritchie, Ellen K, Silver, Richard T, Cortes, Jorge, Lin, Li, Visotcky, Alexis, Baim, Arielle, Harrell, Jill, Helton, Bret, Horowitz, Mary, Flynn, Kathryn E

“…Tyrosine kinase inhibitors (TKIs) have been associated with improved survival of patients with chronic myeloid leukemia (CML) but are also associated with…”
Get more information

A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma by Guru Murthy, Guru Subramanian, Kearl, Tyce J, Cui, Weiguo, Johnson, Bryon, Hoffmeister, Karin, Szabo, Aniko, Aoki, Kazuhiro, Harrington, Alexandra M., Carlson, Karen, Michaelis, Laura C., Runaas, Lyndsey, Abedin, Sameem, Duvall, Adam S, Stock, Wendy, Shah, Bijal D., Leonard, Jessica, Pratz, Keith W., Luger, Selina M., Badar, Talha, Baim, Arielle, Yaghoubi, Shahriar, Atallah, Ehab L.

“…Background: Outcomes of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoma (T-ALL or T-LBL respectively) and acute myeloid…”
Get full text

A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML) by Guru Murthy, Guru Subramanian Guru, Kaufmann, Scott H., Szabo, Aniko, Baim, Arielle, Anshu, Ashish, Hinman, Alexander, Michaelis, Laura C., Abedin, Sameem, Carlson, Karen-Sue B., Runaas, Lyndsey, Atallah, Ehab L.

“…Background: Outcomes of patients with AML have remained poor despite the availability of cytotoxic chemotherapy, hypomethylating agents (HMAs) and targeted…”
Get full text

Phase I Study of Combination Chemotherapy Plus Ixazomib in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma (ALL) by Atallah, Ehab, Michaelis, Laura C, Carlson, Karen B., D'Souza, Anita, Fenske, Timothy S., Pasquini, Marcelo C., Hamadani, Mehdi, Baim, Arielle, Guhl, Jessica, Parameswaran, Hari

“…Introduction: The outcome of adult patients with relapsed/refractory ALL remains dismal. In pediatric patients with relapsed/refractory ALL, the combination of…”
Get full text

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey by George, Gemlyn, Atallah, Ehab L., Mauro, Michael J., Goldberg, Stuart L., Baim, Arielle, Guhl, Jessica, Hinman, Alexander, Cortes, Jorge E., Deininger, Michael W., Druker, Brian J., Kota, Vamsi K, Larson, Richard A., Lipton, Jeffrey H., Moore, Joseph O., Oehler, Vivian G., Pinilla Ibarz, Javier, Radich, Jerald, Ritchie, Ellen K., Schiffer, Charles A., Shah, Neil P., Silver, Richard T., Sweet, Kendra L., Thompson, James E., Wadleigh, Martha, Flynn, Kathryn E

“…Introduction: The development of tyrosine kinase inhibitors (TKIs) has markedly improved the prognosis of patients (pts) with chronic myeloid leukemia (CML),…”
Get full text

Patients’ perspectives on the definition of cure in chronic myeloid leukemia by Flynn, Kathryn E., Mauro, Michael J., George, Gemlyn, Hinman, Alexander, Baim, Arielle, Kota, Vamsi, Larson, Richard A., Lipton, Jeffrey H., Thompson, James E., Wadleigh, Martha, Atallah, Ehab

Get full text

Results from the U.S. Life after Stopping TKIs (LAST) Study by Atallah, Ehab, Schiffer, Charles A., Radich, Jerald P., Weinfurt, Kevin, Zhang, Mei-Jie, Kota, Vamsi, Pinilla-Ibarz, Javier, Moore, Joseph O., Larson, Richard A., Oehler, Vivian, Mauro, Michael J., Deininger, Michael W., Thompson, James E., Shah, Neil P., Wadleigh, Martha, Ritchie, Ellen K, Silver, Richard T, Cortes, Jorge E., Baim, Arielle, Horowitz, Mary M., Flynn, Kathryn

“…Background: Several studies have demonstrated the safety of stopping tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia (CML) with a…”
Get full text